Convalescent plasma treatment in severely immunosuppressed patients hospitalized with COVID-19: an observational study of 28 cases

References

• World Health Organization. Statement on the second meeting of the International Health Regulations 2005. Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV); 2020. Available from: https://www.who.int/news/item/30-01-2020-statement-on-the-second-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-outbreak-of-novel-coronavirus-(2019-ncov.
   Google Scholar
• Kos I, Balensiefer B, Roth S, et al. Prolonged course of COVID-19-Associated pneumonia in a B-Cell depleted patient after rituximab. Front Oncol. 2020;10:1578.
   PubMed Web of Science ®Google Scholar
• Luciani M, Bentivegna E, Spuntarelli V, et al. Recurrent COVID-19 pneumonia in the course of chemotherapy: consequence of a weakened immune system? J Med Virol. 2021;93(4):1882–1884.
   PubMed Web of Science ®Google Scholar
• Daoussis D, Leonidou L, Kalogeropoulou C, et al. Protracted severe COVID-19 pneumonia following rituximab treatment: caution needed. Rheumatol Int. 2021;41(10):1839–1843.
   PubMed Web of Science ®Google Scholar
• Yasuda H, Mori Y, Chiba A, et al. Resolution of one-year persisting COVID-19 pneumonia and development of immune thrombocytopenia in a follicular lymphoma patient with preceding rituximab maintenance therapy: a follow-up report and literature review of cases with prolonged infections. Clin Lymphoma Myeloma Leuk. 2021;21:e810–e816.
   PubMed Web of Science ®Google Scholar
• Duléry R, Lamure S, Delord M, et al. Prolonged in-hospital stay and higher mortality after covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy. Am J Hematol. 2021;96(8):934–944.
   PubMed Web of Science ®Google Scholar
• Avouac J, Drumez E, Hachulla E, et al. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study. Lancet Rheumatol. 2021;3(6):e419–e426.
   PubMedGoogle Scholar
• Simonovich VA, Burgos Pratx LD, Scibona P, et al. A randomized trial of convalescent plasma in covid-19 severe pneumonia. N Engl J Med. 2021;384(7):619–629.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang W, Hu Y, et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324(5):460–470.
   PubMed Web of Science ®Google Scholar
• Agarwal A, Mukherjee A, Kumar G, et al. Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID trial). BMJ. 2020;371:m3939.
   PubMed Web of Science ®Google Scholar
• Libster R, Pérez Marc G, Wappner D, et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384(7):610–618.
   PubMed Web of Science ®Google Scholar
• Bégin P, Callum J, Jamula E, et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med. 2021;27(11):2012–2024.
   PubMed Web of Science ®Google Scholar
• Rojas M, Rodríguez Y, Monsalve DM, et al. Convalescent plasma in covid-19: possible mechanisms of action. Autoimmun Rev. 2020;19(7):102554.
   PubMed Web of Science ®Google Scholar
• Hueso T, Pouderoux C, Péré H, et al. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. 2020;136(20):2290–2295.
   PubMed Web of Science ®Google Scholar
• Betrains A, Godinas L, Woei-A-Jin FJSH, et al. Convalescent plasma treatment of persistent severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection in patients with lymphoma with impaired humoral immunity and lack of neutralising antibodies. Br J Haematol. 2021;192(6):1100–1105.
   PubMed Web of Science ®Google Scholar
• Ormazabal Vélez I, Induráin Bermejo J, Espinoza Pérez J, et al. Two patients with rituximab associated low gammaglobulin levels and relapsed Covid-19 infections treated with convalescent plasma. Transfus Apher Sci. 2021;60(3):103104.
   PubMed Web of Science ®Google Scholar
• Delgado-Fernández M, García-Gemar GM, Fuentes-López A, et al. Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency - three consecutive cases and review of the literature. Enferm Infecc Microbiol Clin. 2021. DOI:https://doi.org/10.1016/j.eimc.2021.01.013
   Web of Science ®Google Scholar
• Rodionov RN, Biener A, Spieth P, et al. Potential benefit of convalescent plasma transfusions in immunocompromised patients with COVID-19. Lancet Microb. 2021;2(4):e138.
   PubMedGoogle Scholar
• Region Skåne. Population in Skåne; 2020 [cited 2021 Jan 10]. https://utveckling.skane.se/digitala-rapporter/huga/befolkning/.
   Google Scholar
• Holm K, Lundgren MN, Kjeldsen-Kragh J, et al. Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden. BMC Res Notes. 2021;14:440.
   PubMed Web of Science ®Google Scholar
• Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383.
   PubMedGoogle Scholar
• Infection W. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20(8):e192–e197.
   PubMed Web of Science ®Google Scholar
• Fung M, Nambiar A, Pandey S, et al. Treatment of immunocompromised COVID-19 patients with convalescent plasma. Transpl Infect Dis. 2021;23(2):e13477.
   PubMed Web of Science ®Google Scholar
• Ferrari S, Caprioli C, Weber A, et al. Convalescent hyperimmune plasma for chemo-immunotherapy induced immunodeficiency in COVID-19 patients with hematological malignancies. Leuk Lymphoma. 2021;62(6):1490–1496.
   PubMed Web of Science ®Google Scholar
• Biernat MM, Kolasińska A, Kwiatkowski J, et al. Early administration of convalescent plasma improves survival in patients with hematological malignancies and COVID-19. Viruses. 2021;13(3):436.
   PubMed Web of Science ®Google Scholar
• Thompson MA, Henderson JP, Shah PK, et al. Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19. JAMA Oncol. 2021;7(8):1167.
   Web of Science ®Google Scholar
• Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with covid-19. N Engl J Med. 2021;384(3):238–251.
   PubMed Web of Science ®Google Scholar
• Strålin K, Wahlström E, Walther S, et al. Mortality in hospitalized COVID-19 patients was associated with the COVID-19 admission rate during the first year of the pandemic in Sweden. Infect Dis. 2021;1–7. DOI:https://doi.org/10.1080/23744235.2021.1983643
   Google Scholar
• Søfteland JM, Friman G, von Zur-Mühlen B, et al. COVID-19 in solid organ transplant recipients: a national cohort study from Sweden. Am J Transplant. 2021;21(8):2762–2773.
   PubMed Web of Science ®Google Scholar
• Sanchez-Pina JM, Rodríguez Rodriguez M, Castro Quismondo N, et al. Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. Eur J Haematol. 2020;105(5):597–607.
   PubMed Web of Science ®Google Scholar
• Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881–2892.
   PubMed Web of Science ®Google Scholar
• Loarce-Martos J, García-Fernández A, López-Gutiérrez F, et al. High rates of severe disease and death due to SARS-CoV-2 infection in rheumatic disease patients treated with rituximab: a descriptive study. Rheumatol Int. 2020;40(12):2015–2021.
   PubMed Web of Science ®Google Scholar
• Gupta A, Desai N, Sanjeev Chauhan P, et al. Clinical profile and outcome of COVID-19 in haematological malignancies: experience from tertiary care Centre in India. Ann Hematol. 2021. DOI:https://doi.org/10.1007/s00277-021-04644-3
   Google Scholar
• Group RC, Horby PW, Mafham M, et al. Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv. 2021. DOI:https://doi.org/10.1101/2021.06.15.21258542
   Google Scholar